# OnCo record truemrd (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/truemrd/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "truemrd" ;
  schema:name "TrueMRD"@en ;
  schema:alternateName "Veracyte TrueMRD"@en, "TrueMRD Monitoring Test"@en, "TrueMRD" ;
  schema:description "Veracyte's whole-genome blood test for bladder cancer coming back after treatment, built on C2i Genomics' method and Medicare-covered from launch in June 2026."@en ;
  schema:url <https://onco.cc/drugs/truemrd/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.veracyte.com/tests/truemrd-mibc/>, <http://web.archive.org/web/20260515145710/https://investor.veracyte.com/news-releases/news-release-details/veracyte-secures-medicare-coverage-truemrd-monitoring-test>, <http://web.archive.org/web/20250813165011/https://investor.veracyte.com/news-releases/news-release-details/veracyte-completes-acquisition-c2i-genomics>, <https://doi.org/10.1016/j.eururo.2024.05.014>, <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58376> ;
  onco:status "emerging" ;
  onco:tag "test" ;
  onco:modality "Tumour-informed whole-genome ctDNA minimal residual disease test" ;
  onco:related <https://onco.cc/drugs/signatera/> ;
  onco:cancers <https://onco.cc/cancers/muscle-invasive-bladder-cancer/>, <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:companies <https://onco.cc/companies/veracyte/>, <https://onco.cc/companies/c2i-genomics/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> .